CPTR

AcronymDefinition
CPTRCertified Professional Tarot Reader (Canadian Tarot Network; Calgary, Alberta, Canada)
CPTRClinical Pharmacology and Translational Research (American Association of Pharmaceutical Scientists)
CPTRCenter for Public Television and Radio (University of Alabama; Tuscaloosa, AL)
CPTRCurrent Public Transport Records (South Africa)
CPTRCapital Projects Technology Roadmap
CPTRCertified Proof Test Report
References in periodicals archive ?
(CSE: CPTR) (FRANKFURT: NMV) (USOTC: NWURF) has closed its acquisition of California, US-based cannabis company Mellow Extracts, LLC, the company said.
This has lead to a revolutionary cross-sector initiative called the Critical Path to TB Regimens (CPTR), which is a collaboration of pharmaceutical companies; government/ regulatory agencies; donors; academia; advocates- all having the common aim to accelerate the development of new, safe, and highly effective tuberculosis (TB) treatment regimens with shorter therapy durations.
The goal of the new CPTR Initiative is to bring together the sponsors of these different new drugs that are in the development stage, the regulatory authorities, and other key stakeholders, including funders, to really change the paradigm of the clinical process.
Canada-based investment firm Captor Capital Corp.'s (CSE: CPTR) (FRANKFURT: NMV) (OTC: NWURF) acquisition of all of the outstanding securities of US-based recreational cannabis dispensaries operator I-5 Holdings Ltd.
1 March 2018 - Canada-based investment firm Captor Capital Corp.'s (CSE: CPTR) (FRANKFURT: NMV) (OTC: NWURF) acquisition of all of the outstanding securities of US-based recreational cannabis dispensaries operator I-5 Holdings Ltd.
Only then will the Critical Path To TB Drug Regimens (CPTR) will make an impact by accelerating the development and delivery of new and improved TB treatment regimens, and by sharing data among the CPTR partners promotes an efficient development model that puts patient needs first.
We all hope that CPTR will make a positive difference in the lives of millions of TB patients all over the world.
This innovative model is part of a wider programme called the 'Critical Path To TB Drug Regimens (CPTR)' which was launched by FDA Commissioner Margaret Hamburg on March 17, 2010, and is led by the Bill and Melinda Gates Foundation, the TB Alliance, and the Critical Path Institute.
The Critical Path to TB Regimens (CPTR) Initiative is a cross sector initiative, which purports to reduce the amount of time needed to register novel regimens for tuberculosis and drug-resistant tuberculosis from decades to years.